Tags

Type your tag names separated by a space and hit enter

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Breast Cancer Res Treat. 2011 Jun; 127(3):713-20.BC

Abstract

Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (i) Luminal A (ER-positive, PgR-positive, HER2-negative and Ki-67 < 14%); (ii) Luminal B (ER-positive and/or PgR-positive, HER2-positive and/or Ki-67 ≥ 14%); (iii) HER2-positive, both endocrine receptors absent; and (iv) Triple Negative. At multivariate analysis, women with the Triple Negative breast cancer subtype had an increased risk of loco-regional relapse (LRR) (Hazards Ratio (HR) 3.58; 95%CI: 1.40-9.13) and breast cancer related events (HR 2.18; 95%CI: 1.04-4.57). Overall, Luminal B subtype was not associated with a statistically significant increased risk of recurrence compared with Luminal A, while patients with Luminal B subtype tumours overexpressing HER2 had a 2 fold risk of reduced breast cancer related survival (BCS), but not an increased risk of LRR and distant metastases. Women with HER2 breast cancer subtype had a statistically significant increased risk of LRR (HR 4.53; 95%CI: 1.56-13.1), distant metastases and reduced BCS (HR 3.22; 95%CI: 1.44-7.18) and overall survival (HR 2.87; 95%CI: 1.05-7.89) when compared with the Luminal A subtype, at multivariate analysis. In conclusion, women with small size, node-negative, breast cancer are at higher risk of relapse if with HER2-positive endocrine receptor absent or Triple Negative disease.

Authors+Show Affiliations

Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. giuseppe.cancello@ieo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21452022

Citation

Cancello, G, et al. "Prognosis in Women With Small (T1mic,T1a,T1b) Node-negative Operable Breast Cancer By Immunohistochemically Selected Subtypes." Breast Cancer Research and Treatment, vol. 127, no. 3, 2011, pp. 713-20.
Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat. 2011;127(3):713-20.
Cancello, G., Maisonneuve, P., Rotmensz, N., Viale, G., Mastropasqua, M. G., Pruneri, G., Montagna, E., Dellapasqua, S., Iorfida, M., Cardillo, A., Veronesi, P., Luini, A., Intra, M., Gentilini, O., Scarano, E., Goldhirsch, A., & Colleoni, M. (2011). Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Research and Treatment, 127(3), 713-20. https://doi.org/10.1007/s10549-011-1465-7
Cancello G, et al. Prognosis in Women With Small (T1mic,T1a,T1b) Node-negative Operable Breast Cancer By Immunohistochemically Selected Subtypes. Breast Cancer Res Treat. 2011;127(3):713-20. PubMed PMID: 21452022.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. AU - Cancello,G, AU - Maisonneuve,P, AU - Rotmensz,N, AU - Viale,G, AU - Mastropasqua,M G, AU - Pruneri,G, AU - Montagna,E, AU - Dellapasqua,S, AU - Iorfida,M, AU - Cardillo,A, AU - Veronesi,P, AU - Luini,A, AU - Intra,M, AU - Gentilini,O, AU - Scarano,E, AU - Goldhirsch,A, AU - Colleoni,M, Y1 - 2011/03/31/ PY - 2011/02/16/received PY - 2011/03/16/accepted PY - 2011/4/1/entrez PY - 2011/4/1/pubmed PY - 2011/12/13/medline SP - 713 EP - 20 JF - Breast cancer research and treatment JO - Breast Cancer Res Treat VL - 127 IS - 3 N2 - Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (i) Luminal A (ER-positive, PgR-positive, HER2-negative and Ki-67 < 14%); (ii) Luminal B (ER-positive and/or PgR-positive, HER2-positive and/or Ki-67 ≥ 14%); (iii) HER2-positive, both endocrine receptors absent; and (iv) Triple Negative. At multivariate analysis, women with the Triple Negative breast cancer subtype had an increased risk of loco-regional relapse (LRR) (Hazards Ratio (HR) 3.58; 95%CI: 1.40-9.13) and breast cancer related events (HR 2.18; 95%CI: 1.04-4.57). Overall, Luminal B subtype was not associated with a statistically significant increased risk of recurrence compared with Luminal A, while patients with Luminal B subtype tumours overexpressing HER2 had a 2 fold risk of reduced breast cancer related survival (BCS), but not an increased risk of LRR and distant metastases. Women with HER2 breast cancer subtype had a statistically significant increased risk of LRR (HR 4.53; 95%CI: 1.56-13.1), distant metastases and reduced BCS (HR 3.22; 95%CI: 1.44-7.18) and overall survival (HR 2.87; 95%CI: 1.05-7.89) when compared with the Luminal A subtype, at multivariate analysis. In conclusion, women with small size, node-negative, breast cancer are at higher risk of relapse if with HER2-positive endocrine receptor absent or Triple Negative disease. SN - 1573-7217 UR - https://www.unboundmedicine.com/medline/citation/21452022/Prognosis_in_women_with_small__T1micT1aT1b__node_negative_operable_breast_cancer_by_immunohistochemically_selected_subtypes_ L2 - https://doi.org/10.1007/s10549-011-1465-7 DB - PRIME DP - Unbound Medicine ER -